share_log

HC Wainwright & Co. Reiterates Neutral on NovoCure, Maintains $22 Price Target

Benzinga ·  Mar 12 22:23

HC Wainwright & Co. analyst Emily Bodnar reiterates NovoCure (NASDAQ:NVCR) with a Neutral and maintains $22 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment